Treated prevalence, incidence, and pharmacotherapy of child and adolescent mood disorders in an HMO.
Treated prevalence, incidence, and pharmacotherapy of child and adolescent mood disorders in an HMO.
复制标题
DOI：
10.1023/a:1011512901714
复制
发表时间：
2001-06-01
期刊：
影响因子：
--
通讯作者：
Nichols, G A
中科院分区：
文献类型：
--
作者：
DeBar, L L;Clarke, G N;Nichols, G A
本研究探讨了在管理性护理环境中儿童和青少年情绪障碍的“治疗”患病率、发病率和药物治疗。各年龄和性别的一般流行模式与社区流行病学研究报告的情况相似，但总体发病率略低，这并不令人意外。初级保健提供者确定了相当大比例的青年患有情绪障碍。在医疗机构中被确定患有情绪障碍的青少年比在专业精神卫生保健机构中被确定患有情绪障碍的青少年更经常使用抗抑郁药物。这些结果对于确定接受药物处方的情绪障碍青少年是否根据当前最佳实践指南（如成人抑郁症指南[美国卫生与公众服务部，1993]）进行治疗，即主要使用SSRI药物是有价值的。
This study examined the "treated" prevalence, incidence, and pharmacotherapy of child and adolescent mood disorders in a managed care setting. General prevalence patterns across age and sex were similar to those reported in community epidemiology studies, although, not unexpectedly, the overall rates were somewhat lower. Primary care providers identified a substantial proportion of the youth with a mood disorder. Antidepressant medication was used more often by youth identified with a mood disorder in medical care settings than by those youth identified in specialty mental health care settings. These results are valuable in determining if youth with mood disorders receiving medication prescriptions across settings are treated according to current best practice guidelines (such as the adult depression guidelines [U.S. Department of Health and Human Services, 1993]), that is, primarily with SSRI medications.